Module

Investigational Small Molecule Agents for the Treatment of Chronic Hepatitis C

Source: The Future of HCV: Small Molecules in Development for Chronic Hepatitis C

Investigational Small Molecule Agents for the Treatment of Chronic Hepatitis C

Program Director: Raymond T. Chung, MD

Faculty:

Gary L. Davis, MD

CME CREDIT INFORMATION

Release Date: 07/16/07

Expiration Date: 07/15/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

List steps in the hepatitis C virus (HCV) life cycle that present opportunities for therapeutic intervention
Discuss emerging efficacy and safety data on small-molecule specifically targeted anti-HCV agents
Describe the current understanding of resistance mutations with new therapies

Topics covered include:

Introduction
Agents That Block Cell Entry
Blocking HCV RNA Transport
Viral Protease Inhibitors
Viral Polymerase Inhibitors and Other Inhibitors of Transcription
Inhibition of Virus Assembly and Release
Conclusions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.